혈관부종 치료 시장 : 약제 클래스별, 투여 경로별, 질환 유형별, 최종 사용자별, 유통 채널별 - 시장 예측(2026-2032년)

The Angioedema Treatment Market was valued at USD 6.47 billion in 2025 and is projected to grow to USD 7.62 billion in 2026, with a CAGR of 18.60%, reaching USD 21.36 billion by 2032.

An immersive introduction to the clinical complexity, diagnostic evolution, and therapeutic momentum transforming angioedema care and stakeholder priorities

Angioedema presents a heterogeneous clinical challenge characterized by episodic tissue swelling, potentially life-threatening airway compromise, and variable triggers that span genetic, immunologic, and idiopathic pathways. Contemporary care paradigms are being reshaped by a deeper mechanistic understanding of bradykinin-mediated pathways, improved diagnostic algorithms, and an expanding therapeutic armamentarium that emphasizes targeted molecular interventions. Clinicians increasingly prioritize rapid onset of action, durable prophylaxis for high-risk patients, and treatment regimens that support outpatient and home-based administration to reduce emergency utilization and improve quality of life.

Payers and health systems are adapting protocols to balance acute care needs against long-term management costs and patient adherence. Meanwhile, research investments are moving toward precision approaches that seek to stratify patients by underlying disease mechanism and response predictors. Translational efforts now focus on biomarker-driven diagnostics and novel delivery platforms that can address both hereditary and acquired forms of angioedema. Taken together, these forces are driving a transition from episodic rescue therapy toward integrated care pathways that emphasize prophylaxis, personalized treatment selection, and cross-disciplinary coordination among immunology, allergy, and emergency medicine specialists.

How therapeutic innovation, outpatient care expansion, and regulatory evolution are converging to redefine treatment paradigms and commercial imperatives in angioedema

The landscape for angioedema treatment is undergoing transformative shifts driven by advances in molecularly targeted therapies, expanded outpatient care models, and evolving regulatory and payer expectations. Precision therapeutics that target the bradykinin pathway and kallikrein activity are redefining clinical endpoints, with stakeholders increasingly focused on reducing attack frequency and preventing airway compromise rather than merely treating acute episodes. Simultaneously, the move toward self-administration and home-based care is altering product design priorities, favoring formulations and devices that combine ease of use with robust safety and stability profiles.

Regulatory frameworks are also maturing to accommodate novel biologics and small-molecule inhibitors, prompting sponsors to design evidence packages that emphasize patient-reported outcomes and long-term safety. In parallel, digital health tools and remote monitoring are creating opportunities for earlier intervention and improved adherence, enabling tighter integration between specialty clinics and home care providers. These shifts create new competitive dynamics, where value demonstration, real-world evidence generation, and cross-stakeholder alignment will determine which products achieve sustainable uptake across diverse care settings.

Assessing the operational and strategic consequences of tariff-driven supply chain shifts and procurement adaptations for angioedema therapeutics in the United States

Tariff dynamics and trade policy adjustments in the United States can materially influence the economics and logistics of angioedema therapeutics by affecting input costs, import timelines, and supplier selection. When tariff-related cost pressures rise, manufacturers and distributors often respond by reassessing sourcing strategies, accelerating qualification of alternative suppliers, or localizing manufacturing steps to reduce exposure to cross-border duties. These supply chain adaptations can lead to reevaluation of inventory buffers, longer lead times for complex biologics, and shifts in distribution networks that prioritize reliability and predictability.

Healthcare providers and payers may experience indirect effects as procurement processes incorporate new cost and availability considerations, prompting renegotiations of contracts or the exploration of alternative therapeutic classes where clinically appropriate. Manufacturers can mitigate tariff-related disruptions by diversifying supply chains across geographies, investing in onshore fill-finish capabilities, and enhancing transparency with trading partners to anticipate policy shifts. In addition, strategic use of advance purchase commitments and tiered pricing arrangements can preserve access in vulnerable patient populations while maintaining commercial viability under evolving tariff conditions.

Segment-driven insights that connect therapeutic mechanisms, delivery formats, disease heterogeneity, care settings, and distribution channels to pragmatic commercialization choices

A granular segmentation lens reveals how clinical and commercial strategies must align to address distinct therapeutic classes, administration preferences, disease etiologies, care settings, and distribution pathways. Based on drug class, product developers must differentiate value propositions for bradykinin receptor antagonists, C1 inhibitors, and kallikrein inhibitors by linking mechanism-specific outcomes to patient-centric endpoints and payer-relevant measures. This requires targeted evidence generation that speaks to the comparative advantages of each modality in reducing attack severity and improving long-term disease control. Based on administration route, the market is influenced by the practical trade-offs between injectable therapies that often deliver rapid onset and oral agents that offer convenience and adherence benefits; developers must therefore optimize formulation and delivery technology to match intended care settings.

Based on disease type, the needs of patients with acquired, hereditary, and idiopathic forms diverge in diagnostic complexity, genetic counseling requirements, and prophylaxis versus rescue therapy priorities, demanding differentiated clinical pathways and patient education. Based on end user, home care, hospitals, and specialty clinics present unique adoption barriers and training needs, shaping how product support programs and clinical services are structured. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy dynamics influence access, reimbursement pathways, and patient convenience, requiring tailored commercial strategies that account for regulatory, logistical, and payer nuances across each channel.

Regional strategies for aligning regulatory, reimbursement, and access approaches across the Americas, Europe Middle East & Africa, and Asia-Pacific to optimize patient reach

Regional dynamics exert a defining influence on development priorities, regulatory alignment, and access pathways for angioedema treatments, requiring differentiated approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, stakeholder emphasis is commonly placed on demonstrating clear clinical value and payer-aligned outcomes to secure formulary placement and outpatient adoption while also supporting home administration programs that reduce acute care burden. Regulatory review processes in this region often encourage robust clinical endpoints and post-approval safety monitoring, shaping evidence strategies that prioritize real-world data collection.

Across Europe, Middle East & Africa, diverse national regulatory regimes and procurement models necessitate flexible market-entry strategies and tailored health-technology assessment dossiers. Manufacturers must be prepared to engage diverse payer panels and adopt adaptive pricing approaches to accommodate public tendering processes and regional reimbursement variability. In the Asia-Pacific region, rapid innovation adoption in some markets is counterbalanced by infrastructure and access disparities in others, creating opportunities for tiered market entry, local partnerships, and capacity-building initiatives that support training for specialty clinics and home-care networks. Across all regions, coordinated regulatory planning and early payer engagement enhance the likelihood of timely access for patients.

How leading developers are pairing mechanism-focused portfolios with delivery innovations, supply-chain partnerships, and patient-centric support to win clinical and commercial adoption

Key company-level behaviors in the angioedema landscape reflect a combination of platform investment, targeted clinical development, and commercial ecosystem building. Leading developers are prioritizing mechanism-specific portfolios while investing in formulation technologies that facilitate self-administration and outpatient use. Strategic alliances with contract manufacturing and logistics providers are increasingly common as firms seek to de-risk supply chains and secure reliable channels for biologic fill-finish and cold-chain distribution.

Commercially, firms are creating integrated patient support services that combine training, adherence tools, and reimbursement navigation to lower barriers to adoption among home care users and specialty clinics. On the evidence front, sponsors are expanding real-world data programs and patient-reported outcome initiatives to supplement pivotal clinical studies and to meet payer expectations for longitudinal effectiveness and safety. Competitive differentiation is emerging through service models as much as product attributes, with successful organizations demonstrating the ability to align clinical benefits with pragmatic delivery and support systems that resonate with clinicians, payers, and patients alike.

Actionable recommendations for executives to align R&D, supply chain resilience, payer engagement, and patient-centric services for sustainable angioedema product adoption

Industry leaders should adopt a multi-dimensional strategy that integrates clinical differentiation, supply resilience, and payer-aligned value demonstration. First, prioritize development programs that clearly link mechanism of action to clinically meaningful endpoints and patient-reported outcomes, ensuring that evidence generation plans address both acute and prophylactic use cases. Second, invest in delivery formats and training programs that enable safe, effective home administration while minimizing the burden on specialty clinics and emergency services. Third, build supply-chain flexibility by qualifying multiple suppliers, exploring local manufacturing partnerships where feasible, and enhancing visibility across distribution layers to preempt disruptions.

Additionally, engage payers early with transparent value dossiers and real-world evidence plans that demonstrate cost-offsets associated with reduced emergency interventions and improved work productivity. Strengthen commercial propositions by aligning distribution strategies with channel-specific access considerations, coordinating with hospital pharmacies, online dispensaries, and retail networks to optimize availability. Finally, develop service-oriented differentiation-patient support, digital adherence tools, and clinician education-to accelerate uptake and sustain long-term adherence across diverse patient cohorts.

A transparent mixed-methods methodology integrating secondary synthesis, targeted stakeholder interviews, and rigorous triangulation to produce decision-focused insights

The research approach combines systematic secondary review, structured primary inquiry, and rigorous triangulation to ensure robust, decision-grade findings. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical practice statements, and publicly available safety and efficacy data to map the clinical landscape and identify mechanistic differentiators. Primary research involved semi-structured interviews with a cross-section of stakeholders, including specialists in immunology and allergy, procurement officials, clinical operations leaders from hospitals and specialty clinics, and patient advocacy representatives to surface adoption barriers and care pathway realities.

Data were triangulated through cross-validation of clinical inputs, supply-chain assessments, and payer perspectives to reconcile divergent viewpoints and highlight consensus-driven implications. Segmentation analysis applied diagnostic, therapeutic, and channel lenses to isolate differential needs across bradykinin receptor antagonists, C1 inhibitors, and kallikrein inhibitors as well as injectable versus oral administration, hereditary versus acquired and idiopathic disease types, and the roles of home care, hospitals, and specialty clinics. Quality control measures included methodological audits, interview verification, and iterative expert review to ensure findings are actionable and replicable.

Concluding synthesis emphasizing the interplay of therapeutic innovation, delivery models, payer engagement, and supply resilience required for meaningful angioedema care advancement

The cumulative analysis underscores a strategic inflection point for angioedema treatment where molecular innovation, delivery optimization, and ecosystem design converge to create new opportunities for improved patient outcomes and differentiated commercial success. Advances in targeted therapeutics and an increased emphasis on home-based care models are shifting clinical practice toward proactive management, while supply chain and policy dynamics require deliberate mitigation strategies to sustain access. Effective commercialization will depend not solely on molecular efficacy but on the ability to demonstrate value to payers, deliver convenient and safe administration options to patients, and ensure distribution reliability across diverse channels.

Looking ahead, organizations that couple robust clinical programs with adaptive supply chains and comprehensive patient support mechanisms will be best positioned to translate scientific progress into meaningful care improvements. Cross-disciplinary collaboration among developers, clinicians, payers, and patient groups will remain essential to align incentives and expedite adoption of therapies that reduce disease burden and enhance long-term quality of life.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Angioedema Treatment Market, by Drug Class

• 8.1. Bradykinin Receptor Antagonists
• 8.2. C1 Inhibitors
• 8.3. Kallikrein Inhibitors

9. Angioedema Treatment Market, by Administration Route

• 9.1. Injectable
• 9.2. Oral

10. Angioedema Treatment Market, by Disease Type

• 10.1. Acquired
• 10.2. Hereditary
• 10.3. Idiopathic

11. Angioedema Treatment Market, by End User

• 11.1. Home Care
• 11.2. Hospitals
• 11.3. Specialty Clinics

12. Angioedema Treatment Market, by Distribution Channel

• 12.1. Hospital Pharmacy
• 12.2. Online Pharmacy
• 12.3. Retail Pharmacy

13. Angioedema Treatment Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Angioedema Treatment Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Angioedema Treatment Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Angioedema Treatment Market

17. China Angioedema Treatment Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. Adverum Biotechnologies, Inc.
• 18.6. Argenx NV
• 18.7. AstraZeneca plc
• 18.8. Attune Pharmaceuticals, Inc.
• 18.9. Aurobindo Pharma Ltd.
• 18.10. Bayer AG
• 18.11. BioCryst Pharmaceuticals, Inc.
• 18.12. Cipla Limited
• 18.13. CSL Behring
• 18.14. Dr. Reddy's Laboratories Ltd.
• 18.15. GlaxoSmithKline plc
• 18.16. HAE Pharma LLC
• 18.17. Intellia Therapeutics, Inc.
• 18.18. Ionis Pharmaceuticals, Inc.
• 18.19. KalVista Pharmaceuticals Ltd.
• 18.20. Merck & Co., Inc.
• 18.21. Novartis AG
• 18.22. Otsuka Pharmaceutical Co., Ltd.
• 18.23. Pfizer Inc.
• 18.24. Pharming Group N.V.
• 18.25. Pharvaris Netherlands B.V.
• 18.26. Sanofi S.A.
• 18.27. Sobi
• 18.28. Takeda Pharmaceutical Company Limited
• 18.29. Teva Pharmaceutical Industries Ltd.